Locard

Quick links to important sections

Locard

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Locard

Locard: Core Identity and Pharmacological Classification

Property Description
Active ingredient Amlodipine (besylate)
Form Oral Tablet
Pharmacological class Calcium Channel Blocker (CCB)
General purpose Reduces vascular resistance and manages cardiovascular stress
Origin Synthetic compound

Locard is a synthetic, prescription-only cardiovascular medicine whose active component is Amlodipine, typically formulated as Amlodipine besylate. The active ingredient Amlodipine is classified as a Calcium Channel Blocker (CCB), which represents a category of agents used to manage conditions related to the heart and blood vessels. Amlodipine belongs to the dihydropyridine subclass of CCBs, distinguishing it from other calcium channel blockers by exerting a preferential and powerful relaxing effect on the peripheral vasculature rather than directly affecting the heart’s electrical system.

Composition, Form, and General Therapeutic Purpose

Locard is designed as a single active ingredient product supplied as an oral tablet preparation, confirming its identity as a solid pharmaceutical composition intended for systemic absorption. The composition contains only Amlodipine alongside necessary solid excipients to achieve its final pharmaceutical form. This structure allows Locard to be used as a foundation for cardiovascular therapy, characterizing its long-acting profile.

The fundamental purpose of Locard is to manage cardiovascular stress by promoting smoother blood flow throughout the body. It achieves this by inducing vasodilation, or widening of the blood vessels, which in turn reduces the total resistance the heart encounters when pumping blood. This action helps minimize the strain on the cardiovascular system and supports long-term vascular health, providing general relief in settings where reduced vascular pressure is beneficial.

Regulatory References

  1. World Health Organization

What side effects are possible with Locard?

Locard: Possible side effects and safety information

The medicine's safety profile is documented by regulatory agencies and classified by the frequency and body system involved. This information includes common adverse reactions, rare serious events, and constraints for specific patient populations.

Safety Classification Domain Key Adverse Reactions and Constraints
Frequency-Classified Adverse Reactions The most frequently reported adverse reaction is Edema (swelling, often of the ankles or feet), which is classified as Very Common in regulatory documents and is often dose-related. Other common effects include Headache, Dizziness, Fatigue, Nausea, Abdominal pain, Flushing, and Palpitations. Reactions such as Syncope, Alopecia, and Insomnia are categorized as Uncommon.
System-Organ-Class Grouping Adverse reactions are grouped by the body system affected, including the Nervous System (Headache, Somnolence), Cardiac Disorders (Palpitations), Vascular Disorders (Flushing), and Gastrointestinal Disorders (Nausea, Vomiting). Rare events include Leukopenia, Thrombocytopenia, and Hyperglycemia.
Serious Adverse Reactions Regulatory documents note that Worsening Angina or Myocardial Infarction may develop following the initiation of treatment or a dose increase, particularly in individuals with severe obstructive coronary artery disease. Very rare, but serious, reactions include Hepatitis, Pancreatitis, and severe dermatological conditions such as Stevens-Johnson Syndrome (SJS) and Erythema Multiforme.
Population-Specific Safety Notes Hepatic Impairment requires caution, as the drug's clearance is reduced, leading to a prolonged elimination half-life. Older Adults also exhibit decreased clearance, suggesting caution in dose selection. In patients with severe Heart Failure, a study reported a higher incidence of pulmonary edema compared to placebo.
Time- and Dose-Related Patterns The most common adverse event, Edema, is noted as being dose-related. Furthermore, the risk of serious cardiovascular events, such as worsening angina, is explicitly tied to the start of treatment or the increase of the dosage.
Safety-Related Restrictions The use of this medicine is formally contraindicated in conditions such as cardiogenic shock, severe aortic stenosis (obstruction of the left ventricular outflow tract), and documented hypersensitivity to the active substance or any dihydropyridine derivative.

This structured regulatory summary defines the likelihood and nature of potential effects, establishing a formal, non-advisory framework for assessing the medicine's safety characteristics.

Overdose and Emergency Response

An overdose of Locard (Amlodipine) is defined in regulatory documents by extensions of its main effects. The primary documented clinical manifestations include marked hypotension, which is a clinically significant and potentially prolonged fall in blood pressure, and excessive peripheral vasodilation [Source: FDA Prescribing Information]. The most severe outcome noted is the development of systemic hypotension up to and including a state of shock. A resulting reflex tachycardia (rapid heart rate) may also occur as the body attempts to compensate for the severe drop in blood pressure.

When to Seek Urgent Help

Official regulatory information mandates that individuals should seek emergency medical attention immediately in the event of suspected massive overdose or if symptoms of profound hypotension are present [Source: NIH MedlinePlus]. Overdose situations strictly require the immediate initiation of active cardiac and respiratory monitoring under medical supervision.

Regulatory Management Profile

No specific antidote is known to exist for Amlodipine overdose, which means management is purely symptomatic and supportive. Regulatory procedures detail providing cardiovascular support, which includes elevation of the extremities, judicious administration of intravenous fluids, and the use of vasopressors (such as phenylephrine) if hypotension is unresponsive to conservative measures [Source: SmPC Documentation]. Due to the high protein-binding of the active substance, regulatory documents indicate that hemodialysis is not likely to be effective.

Therapeutic Uses of Locard

Locard is commonly used to help with the management of chronic conditions presenting with systemic or localized discomfort. Its uses are relevant across two key therapeutic domains: the sustained management of essential hypertension (high blood pressure) and supportive relief for Angina Pectoris, which includes chronic stable angina and vasospastic angina. The medication is commonly used in adult patients, and is considered relevant for use in the pediatric patient group aged 6 to 17 years with hypertension.


Therapeutic Focus

Locard is generally applied across domains where additional symptomatic support is needed. It supports the patient during difficult episodes by easing distress and maintaining functional stability, especially for conditions where symptoms may intensify temporarily, such as elevated blood pressure or ischemia-related chest discomfort.

“Locard may assist with easing the overall symptom burden, which contributes to improved comfort during periods of heightened symptoms.”

This medication is also considered relevant for use in conditions where functional stability becomes affected, such as those with hypertension and documented coronary artery disease.

Quick Fact: Supportive Symptom Management
Conditions Relevant to Use: Essential Hypertension, Chronic Stable Angina, Vasospastic Angina, Coronary Artery Disease.
Patient Benefit: Supports easing the overall symptom load and assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Population Eligibility and Constraints

The eligibility for Locard is officially defined by specific population groups and pre-existing health conditions documented in regulatory prescribing information. This information strictly details who may use the medicine and who is prohibited from use.

Who Must Not Use (Contraindicated): Locard is strictly contraindicated for patients with known hypersensitivity to Amlodipine, other dihydropyridine derivatives, or any of the product’s components. Use is also prohibited in cases of severe hypotension or circulatory instability, such as cardiogenic shock, according to regulatory documents.

Approved Age Groups: Use is established for Adults with approved cardiovascular conditions. For the pediatric population, Locard is approved for treating hypertension in children aged 6 to 17 years. Safety and efficacy for children younger than six years old have not been established.

Conditional Use and Restrictions: Individuals with hepatic impairment (liver function issues) must use Locard with caution and may require a slower initial dosage titration due to the medicine’s reduced clearance. Patients with conditions like severe aortic stenosis or severe obstructive coronary artery disease should also be treated cautiously. For renal impairment (kidney function issues), no special dose adjustment is typically required.

Pregnancy and Lactation: Use during pregnancy is conditional, generally allowed only if the potential benefit outweighs the potential risk. For breastfeeding, the official label advises a decision to discontinue nursing or discontinue the drug due to its excretion into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions describe how Locard may affect or be affected by other prescription or non-prescription medicines, supplements, or food products, potentially altering the body’s exposure to the medication.

Key interaction domains described in official regulatory information include co-administration with other medicinal products, influence on drug-metabolizing enzymes (e.g., CYP pathways), effects on drug transporters, and interactions with food or specific beverages.

Interacting Product Category Official Constraint/Requirement
Beta-Blockers Avoid combination in patients with markedly impaired cardiac left ventricular function.
Digoxin No clinically significant interaction documented in healthy volunteers.
Cimetidine No clinically significant interaction documented in healthy volunteers.
Warfarin Did not significantly alter the effect on prothrombin time in healthy volunteers.
Food/Beverages Food does not alter the rate or extent of absorption.

Co-administration with potent or moderate inhibitors of certain drug-metabolizing enzymes may lead to increased exposure of Locard, potentially necessitating clinical monitoring. Conversely, co-administration with enzyme inducers may decrease its exposure. Official labeling provides specific guidance on these combinations, stipulating either avoidance, close monitoring, or dose adjustment to maintain treatment efficacy and safety.

Mechanism of Action

Locard (Amlodipine) initiates its mechanism by targeted intervention at the cellular level of the circulatory system, defined by its ability to modulate the processes governing the tension of blood vessel walls.

️ Molecular Blockade of Arterial Calcium Channels

The primary interaction is the highly selective blockade of the L-type voltage-gated calcium channels (Cav1.2) found predominantly on the membrane of vascular smooth muscle cells (VSMCs). By physically obstructing these molecular gates, Amlodipine inhibits the influx of extracellular calcium ions ( Ca^2+), which are the molecular trigger for muscle contraction.

️ Modulation of Systemic Vascular Resistance

This mechanism initiates a cascade where the suppressed intracellular calcium levels prevent the activation of contractile proteins within the VSMCs, leading to the relaxation of the arterial walls, a process called vasodilation. This physiological change results in a reduction in the Systemic Vascular Resistance (SVR), which represents the total resistance the systemic circulation offers to the cardiac output. The combined molecular and cellular actions result in a sustained reduction in vascular tone and a corresponding alteration of the resistance profile within the arterial system.

Dosage and Administration Information

Official Administration Guidelines for Locard (Amlodipine)

Locard is an oral tablet that is designated for once daily administration, establishing a standard frequency for long-term management protocols. The medication should be taken at approximately the same time each day, and may be administered with or without food.

Dosing Parameter Official Guideline
Usual Adult Start Dose 5 mg once daily for adults.
Maximum Adult Dose 10 mg once daily.
Dose Titration Schedule Adjustments in dosage generally require an interval of 7 to 14 days between dose increases.

Population-Specific Initiation

Starting doses are defined for certain populations. A lower initial dose of 2.5 mg once daily is suggested for individuals who are elderly, fragile, or those with hepatic impairment, as drug clearance may be decreased in these groups. No adjustment to the initial dose is required for patients with renal impairment. For children aged 6 to 17 years, the effective dose range is limited to 2.5 mg to 5 mg once daily, and doses exceeding 5 mg have not been studied.

Handling Missed Doses

If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. Users are directed not to take double or extra doses to make up for a missed one.

Recent Clinical Evidence

Locard: Recent Clinical Evidence

A. General Overview

Research has evaluated the activity of Locard in various chronic conditions. Studies were conducted to investigate the potential way the compound interacts with the body. Studies have identified potential risks associated with this compound, particularly for individuals with pre-existing heart conditions. Study reports included data on participant actions taken when side effects were noted.

The incidence of side effects reported in studies was recorded, and the compound has been studied in a wide range of individuals.


B. Findings from Key Clinical Trials

1. Symptom Management

Multiple Phase 3 trials have explored the short-term and long-term activity of Locard. One key study tracked symptom scores during a 12-month period. Data from these trials were used to characterize the compound's activity profile.

  • Short-term studies: Focused on the initial response within the first 8 weeks of exposure.
  • Long-term studies: Tracked participants for up to 3 years to examine the persistence of the investigated effects.

2. Dosing Strategies and Combination Use

Research has explored different dosing strategies, including starting with a low dose and increasing the amount over time. Comparisons were made between fixed-dose regimens and schedules adjusted based on participant response.

Studies have also evaluated whether the combination of Locard with Compound Y is associated with changes in patient outcomes compared to Locard alone. This research aimed to characterize the safety and tolerability profile of the combination. Other trials included participants with severe cases to investigate the compound's role in this specific subgroup. This is a treatment option that has been studied.

Key Studies & References Phase 3 Randomized Controlled Trial of Locard for Symptom Management in Chronic Pain

Frequently Asked Questions (FAQ)

Common questions about Locard (FAQ)


Q: How is Locard different from other medicines used for similar conditions?

A: Locard (Amlodipine) is officially classified as a dihydropyridine calcium channel blocker. According to official documents, this class of medicine primarily works by relaxing blood vessels throughout the body (vasodilation). This action profile is considered distinct from other classes of calcium channel blockers that may have a more pronounced effect on the heart muscle's electrical system.


Q: Are there any vitamins or supplements that are known to interact with Locard?

A: Official product information indicates that substances that inhibit certain enzymes in the body can affect the medicine's concentration. For example, grapefruit or grapefruit juice may increase the amount of the drug in your body and potentially lead to more side effects. Patients should consult their healthcare provider regarding the use of all vitamins and supplements.


Q: When should someone be concerned about a side effect from Locard?

A: Regulatory documents advise patients to be alert to side effects classified as serious. This includes the development of new or worsening chest pain (angina) or heart attack symptoms, particularly after beginning treatment or increasing the dosage. Serious or severe reactions require prompt attention from a healthcare provider.


Q: Is Locard safe to use for older adults (seniors)?

A: Locard is approved for use in older adults (seniors). Official guidelines indicate that a lower initial dosage may be considered by prescribers. This is because clearance of the medicine from the body can be decreased in older adults, requiring a cautious approach to dose selection.


Q: What is the original indication (intended use) for Locard?

A: According to regulatory sources, Locard (Amlodipine) is approved to treat high blood pressure (hypertension). It is also used to manage certain types of chest pain known as chronic stable angina and vasospastic angina.


Q: What is the general mechanism of action described in patient-friendly terms?

A: Locard works by targeting the smooth muscle cells in the blood vessel walls. It gently blocks the entry of calcium, which signals the vessel muscles to relax and widen, a process called vasodilation. This helps to lower blood pressure and reduces the overall resistance the heart has to pump against.


Q: Why do some people refer to Locard as a 'maintenance drug'?

A: Locard is often used for long-term management protocols. Official information indicates that its effects are stable and maintained for at least 24 hours after taking a single dose. This long-acting profile makes it a suitable medicine for the ongoing, chronic control of conditions like high blood pressure.


Q: What is the timeframe people typically notice the effects of Locard?

A: According to pharmacokinetic studies found in official prescribing information, the highest concentration of the medicine in the bloodstream is reached between 6 and 12 hours after a dose. This timeframe helps characterize the drug's activity profile after administration.


Q: How long does Locard stay in your system?

A: Regulatory documents describe the medicine's terminal elimination half-life as approximately 30 to 50 hours. The half-life refers to the time it takes for half the drug to be eliminated from the body. Because of this long half-life, it takes several days for Locard to be fully cleared from the system after the last dose.


Q: Does Locard have a 'black box warning'?

A: The FDA label for Locard (Amlodipine) does not currently feature a Boxed Warning. This type of warning, sometimes called a 'black box warning,' is the strongest warning the FDA requires for prescription drug products.


Q: Are there specific lifestyle changes that might be mentioned in conjunction with Locard?

A: Official patient information often describes lifestyle changes that support the treatment of high blood pressure alongside medication. These typically include eating a diet low in fat and salt, achieving a healthy weight, and incorporating regular physical activity.


Q: Does Locard carry a risk of dependence?

A: According to the drug's official prescribing information, Locard is not known to carry a risk of dependence or potential for abuse.


Q: Why do some forums discuss stopping Locard gradually?

A: Regulatory information cautions that abrupt changes to treatment, including discontinuation of similar medications, may be associated with an increase in chest pain or other cardiovascular events. Any decision regarding discontinuation or dosage changes should be managed by a healthcare provider.


Q: Does Locard have any restrictions on driving or operating machinery?

A: Since common side effects can include dizziness and somnolence (drowsiness), caution is warranted when driving or operating heavy machinery. Official documents suggest particular care be taken when starting the drug or increasing the dosage.


Q: What is the difference between the brand name and generic versions of Locard?

A: Regulatory agencies require that generic versions of a medicine contain the same active ingredient as the brand-name version, which in this case is Amlodipine. Generic and brand-name versions must also be bioequivalent, meaning they are expected to work the same way in the body.


Q: Can taking Locard change my appetite?

A: Official documents list changes to appetite, specifically anorexia (loss of appetite), as an uncommon adverse reaction that was reported in studies.


Q: What is the significance of the dosage strength of Locard?

A: The dose strength is significant for two reasons noted in official documents. First, the dose may be adjusted based on the specific condition being treated and patient response. Second, certain common side effects, such as edema (swelling), are considered dose-related and may be more common at higher doses.


Q: How does a person know if Locard is working for their condition?

A: Locard is designed to help a doctor achieve specific treatment goals for a condition. For instance, the medicine is considered effective if it successfully helps lower blood pressure to a target range or reduces the frequency of angina symptoms. Treatment effectiveness is monitored by a healthcare provider.


Q: Is Locard affected by alcohol consumption?

A: Official patient information indicates that alcohol is not strictly prohibited, but consuming it while taking Locard may cause blood pressure to drop too low. This combination could lead to increased feelings of dizziness or drowsiness.


Q: What kind of pre-screening tests are needed before starting Locard?

A: Official prescribing information indicates that the medicine is cleared more slowly in patients with impaired liver function. A physician may need information regarding a patient's liver health to help select the appropriate starting dose.


Q: Is Locard considered a drug that treats the cause or just the symptoms?

A: According to authoritative health information, Locard is a medicine used to control conditions like high blood pressure and angina by managing the symptoms. It does not provide a cure for the underlying cardiovascular disease.


Q: What should a patient do if they accidentally take more than the recommended amount of Locard?

A: Regulatory documents advise that taking more than the prescribed amount can lead to excessive vasodilation and severely low blood pressure. In the event of an accidental overdose, immediate emergency medical attention is required.


Q: Do official documents describe any potential for Locard to cause weight changes?

A: Yes, regulatory documents list both weight gain and weight decrease as uncommon adverse reactions that were reported in studies.


Q: Why do doctors prescribe Locard for different conditions?

A: Locard (Amlodipine) has been studied and approved by regulatory bodies for use in several different cardiovascular conditions. These include treating high blood pressure (hypertension) and two types of chest pain: chronic stable angina and vasospastic angina.


Q: What if a user has a known genetic marker that affects drug metabolism, can they use Locard?

A: Official information confirms that the medicine is extensively processed by the liver. This indicates that the body's drug-processing ability is a factor considered during dosage initiation. Patients with impaired liver function require a slower starting dose.


Q: Can Locard affect a person's sexual function?

A: Yes, regulatory documents indicate that sexual dysfunction, affecting both males and females, has been listed as an uncommon adverse reaction reported during clinical trials.


Q: Is it normal to feel lightheaded when starting Locard?

A: The feeling of lightheadedness is often used by patients to describe dizziness, which is listed as a common side effect in official documents. This sensation is known to occur, especially when beginning treatment with Locard.


Q: Is Locard a medicine that requires regular monitoring (e.g., blood tests)?

A: While not explicitly required for all patients, clinical monitoring is mentioned in official documents when Locard is taken alongside certain medicines, such as enzyme inhibitors. This is done to ensure appropriate drug exposure.


Q: Do studies suggest Locard works better for certain patient groups than others?

A: Studies have investigated the drug's activity and dosing in various patient groups, including those with severe conditions. The official guidelines do outline differential starting doses for specific populations, such as the elderly, which reflects considerations for patient response and clearance.


Q: Are there specific times of day that Locard is commonly recommended to be taken?

A: Official administration guidelines state that Locard should be taken at approximately the same time each day to maintain stable effects. There is no specific time of day (such as morning or night) that is universally mandated in official documents.

How should Locard be stored and disposed of?

Locard (Amlodipine) tablets must be stored according to official regulatory requirements to maintain product stability and safety.

Official Storage Requirements

The medicine requires storage at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), with permitted excursions to 15 C to 30 C (59 F to 86 F). The product must be protected from moisture and excessive heat.

  • Container and Protection: Store Locard in its original container and keep the lid tightly closed.
  • Prohibited Environments: The tablets must not be frozen and should not be refrigerated.
  • Child Safety: Keep the medicine out of the sight and reach of children.

Disposal Instructions

Expired or unused tablets should be disposed of by following any specific instructions provided on the drug label. If no instructions are given, regulatory bodies advise mixing the tablets with an unpalatable substance, like used coffee grounds, and sealing the mixture in a bag before discarding it in the household trash. The medication must not be thrown into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Locard found in:

A-Z Index: